US.MRK · Merck & Co.

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.1995542652680404,
        "turnoverUsdM": 1426.1195542214741,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRK",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 141.5658,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.4,
      "take_profit_price": 155.484,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.399108530536081,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 67.2,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.2,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 6
  },
  "market": {
    "ma20": 148.1805,
    "ma50": 139.473,
    "close": 148.08,
    "prevClose": 150.91,
    "avgVolume20": 9795150,
    "volumeRatio": 0.98,
    "changePercent": -1.88
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 6,
    "details": {
      "ret_5d": 0.02187566075495151,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 6,
      "vcp_bonus": 0,
      "vol_ratio": 0.9617399878370673,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.4914179932821994,
      "volat_points": 2,
      "day_range_pct": 0.031266882343775386,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 67.2,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 11.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 78.67,
        "contribution": 11.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 20.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 68,
        "contribution": 20.4
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 61.2,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 11.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 20.4/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 13.2,
      "市場環境": 11.8,
      "情緒分析": 4,
      "技術信號": 20.4,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 1426.1195542214741,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRK",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.21
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 718.2184960000001,
                "ma50": 711.4151976999997,
                "name": "QQQ",
                "close": 741.21002,
                "points": 2
              },
              "spy": {
                "ma20": 765.28299795,
                "ma50": 760.9057979799998,
                "name": "SPY",
                "close": 767.81,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.1995542652680404,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142341110,
                "url": "https://finnhub.io/api/news?id=18eb6f5054f8ad4c717c221678b003c6b07f135ee74630912412805cce4f8085",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1790092186,
                "headline": "3 Reasons to Sell MRK and 1 Stock to Buy Instead"
              },
              {
                "id": 142337732,
                "url": "https://finnhub.io/api/news?id=dfe046c33ca696e292778fcb96f46b698447668bf4466f5ee2b39fd6b5bcb0d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1790083804,
                "headline": "Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?"
              },
              {
                "id": 142337733,
                "url": "https://finnhub.io/api/news?id=ac2334a1ad7d0851eb6c652f776731ce1f86d33abf8f86974e1f9e3fa399b94f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all existing local indications. The new subcutaneous version offers an alternative to intravenous dosing, aimed at faster administration for patients and clinicians. This approval broadens Merck's oncology treatment options in Japan, a key international market for its immunotherapy portfolio. The KEYTRUDA QLEX subcutaneous green light in Japan matters. However, investors...",
                "category": "company",
                "datetime": 1790079266,
                "headline": "Why Is Merck (MRK) In Focus After Japan Cleared A New Dosing Option?"
              },
              {
                "id": 142314339,
                "url": "https://finnhub.io/api/news?id=1c0904ab76802c9b01ae07aa5de94000aea4551454466795cfe266ba7dc8cff0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.",
                "category": "company",
                "datetime": 1790004120,
                "headline": "AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies"
              },
              {
                "id": 142310717,
                "url": "https://finnhub.io/api/news?id=2094a2c5f9c153b52aeda12f343c88808922fee79702e16bb8ec9cad1deb9cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.",
                "category": "company",
                "datetime": 1789988803,
                "headline": "FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week"
              },
              {
                "id": 142265937,
                "url": "https://finnhub.io/api/news?id=b356f0fe197865d9044098d7597c0feaa5c27513b0c969541884a463486bb1c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received a positive opinion from the EMA’s CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The CHMP verdict on KEYTRUDA plus Padcev is only one piece of the wider Merck story...",
                "category": "company",
                "datetime": 1789773124,
                "headline": "What Does Merck (MRK) Mean For EU Bladder Cancer Treatment After CHMP Support?"
              },
              {
                "id": 142233869,
                "url": "https://finnhub.io/api/news?id=5fb9ffd5ba89cfd23cf51fdcef2f1292c4c60707adfdebff107474f4da2ad100",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day.",
                "category": "company",
                "datetime": 1789681804,
                "headline": "Merck (MRK) Outperforms Broader Market: What You Need to Know"
              },
              {
                "id": 142223864,
                "url": "https://finnhub.io/api/news?id=af7eaaa8344807455788124ff567232d313a78a57bf462a62eaefaee3b4205d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Auxier Asset Management, an investment advisory firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Following a strong rebound from the first-quarter decline, the S&P 500 gained 15.2% as accelerating capital spending toward artificial intelligence infrastructure drove significant gains across technology hardware companies. Semiconductor and data-center-related businesses benefited from supply constraints […]",
                "category": "company",
                "datetime": 1789646258,
                "headline": "Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise"
              }
            ],
            "raw_source": [
              {
                "id": 142363780,
                "url": "https://finnhub.io/api/news?id=bb4171ba2315271ffac02d3155801d13d6e8d838f8d2b0f43020c3b412215389",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.",
                "category": "company",
                "datetime": 1790190609,
                "headline": "Wednesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142364010,
                "url": "https://finnhub.io/api/news?id=68d0c47e436df7dea5a9b1c0e4f840488ea26b6b11d592882fd774625d92c6e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]",
                "category": "company",
                "datetime": 1790188934,
                "headline": "Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO"
              },
              {
                "id": 142364160,
                "url": "https://finnhub.io/api/news?id=f60528ea6c067597ae132ae73d0b61262326523dc883c9700c5efb29ee1c5b86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.",
                "category": "company",
                "datetime": 1790186400,
                "headline": "Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines"
              },
              {
                "id": 142364161,
                "url": "https://finnhub.io/api/news?id=ea2f811f2e9293d30038a9fb71dc847d8235944f0f629dcffbac136d4358eb44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with...",
                "category": "company",
                "datetime": 1790185560,
                "headline": "Merck pipeline seen driving potential re-rating as clinical catalysts approach"
              },
              {
                "id": 142363145,
                "url": "https://finnhub.io/api/news?id=5161f374f3deb629630ae40445292e5990c242ecad419df57bade675dd405271",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.",
                "category": "company",
                "datetime": 1790183924,
                "headline": "What Is AbbVie No Longer Telling You?"
              },
              {
                "id": 142362607,
                "url": "https://finnhub.io/api/news?id=f9224ce266c05c94437da6790449ec52563bfa7bdaa99cc8a7fdaacf38f9a8a1",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.",
                "category": "company",
                "datetime": 1790181609,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 142363146,
                "url": "https://finnhub.io/api/news?id=7c6066d745e16db0599e75e745e060580c3f345bfc520df1443e1cb10391555b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.",
                "category": "company",
                "datetime": 1790181437,
                "headline": "What Is The Best Case For Pfizer Stock?"
              },
              {
                "id": 142361985,
                "url": "https://finnhub.io/api/news?id=7a43d0ea90dc5d3eeda494c02a512c975b8a553410c726e640b84d38fbc58a3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office",
                "category": "company",
                "datetime": 1790175751,
                "headline": "Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID"
              },
              {
                "id": 142358849,
                "url": "https://finnhub.io/api/news?id=61805feacc3ee6da25ef098b50d7d4d2f0118e17a8074c3a4f616b5d00ed8e68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.",
                "category": "company",
                "datetime": 1790168501,
                "headline": "4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout"
              },
              {
                "id": 142359495,
                "url": "https://finnhub.io/api/news?id=502b9875a77504a4a5025f8b1711ecaa7a4161bbe46c82c19a1e8f2d9dd324e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "When patients experience prolonged diarrhea and abdominal pain, one condition doctors may consider is inflammatory bowel disease (IBD). In IBD, different parts of the gastrointestinal tract become inflamed, often causing recurring abdominal pain and diarrhea. If left untreated, the inflammation from IBD can lead to serious complications.",
                "category": "company",
                "datetime": 1790168400,
                "headline": "Merck Manuals Details What Patients Need to Know About Inflammatory Bowel Disease"
              },
              {
                "id": 142356652,
                "url": "https://finnhub.io/api/news?id=dc78c6148bdb8b0f980ac9d35410b43cb3c89937fe7e6742b7cbe19af0bad809",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 38.9% over the past six months, topping the S&P 500 by 20.9 percentage points.",
                "category": "company",
                "datetime": 1790158862,
                "headline": "3 Healthcare Stocks with Warning Signs"
              },
              {
                "id": 142356132,
                "url": "https://finnhub.io/api/news?id=12a1aca6f2196b6f2a6ab78450230c02aa685cd32c7c117fa6fe26a2f1160899",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Breakthrough Therapy (BT) Designation - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Breakthrough Therapy (BT) Designation was estimated at US$79.7 Billion in 2025 and is projected to reach US$212.5 Billion by 2032, growing at a C",
                "category": "company",
                "datetime": 1790150940,
                "headline": "Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue"
              },
              {
                "id": 142355284,
                "url": "https://finnhub.io/api/news?id=51ab9e98988f923dfcd39d855daaf690f3e7c11064494a65b302104de35dcb63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1271085883/image_1271085883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Lipfendra and promising intismeran autogene trial results support Merck's multi-year portfolio renewal prospects amid patent cliff risks. Read why MRK is a Hold.",
                "category": "company",
                "datetime": 1790132578,
                "headline": "Merck's Melt-Up Triggers Profit-Taking Risks - Multi-Year Portfolio Renewal (Rating Downgrade)"
              },
              {
                "id": 142341737,
                "url": "https://finnhub.io/api/news?id=d1a0fa717a3205c82feb1b910304a2237ef6e5907fe442d635e0bf4fae4efbd3",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1790104206,
                "headline": "Tuesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142341109,
                "url": "https://finnhub.io/api/news?id=65987387d1514b7c235af5deaf8fb8ee6b664e5bcda5bac2438ba3e4d9c81482",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.",
                "category": "company",
                "datetime": 1790098791,
                "headline": "Was Moderna Stock's Cancer Vaccine Run Visible In Advance?"
              },
              {
                "id": 142340389,
                "url": "https://finnhub.io/api/news?id=fb1bcc02a1f77d65f8d855cd4d814b4de083a62b5eb3190550ea777befc10ca0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1790095207,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 142341110,
                "url": "https://finnhub.io/api/news?id=18eb6f5054f8ad4c717c221678b003c6b07f135ee74630912412805cce4f8085",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1790092186,
                "headline": "3 Reasons to Sell MRK and 1 Stock to Buy Instead"
              },
              {
                "id": 142339930,
                "url": "https://finnhub.io/api/news?id=2c3e4de6af3f8c35fac4c5b093940bb32300ae1ffe5c29d164d195b8e337f04d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.",
                "category": "company",
                "datetime": 1790088711,
                "headline": "Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?"
              },
              {
                "id": 142339888,
                "url": "https://finnhub.io/api/news?id=521f537e1ccd22d016f77968e273dfe4cdf5c5888d6da300c4de98eb6b88ce02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.",
                "category": "company",
                "datetime": 1790085012,
                "headline": "Could You Have Seen Merck Stock's Pipeline Run Coming?"
              },
              {
                "id": 142337683,
                "url": "https://finnhub.io/api/news?id=a6e637512582ae6a2c04e9f5b697d291a6eb434853f96bd82f1ecb7bfceb614d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.",
                "category": "company",
                "datetime": 1790084448,
                "headline": "Why Is JNJ Stock Beating Rivals That Grow Faster?"
              },
              {
                "id": 142337732,
                "url": "https://finnhub.io/api/news?id=dfe046c33ca696e292778fcb96f46b698447668bf4466f5ee2b39fd6b5bcb0d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1790083804,
                "headline": "Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?"
              },
              {
                "id": 142337734,
                "url": "https://finnhub.io/api/news?id=457c8240b071eef18a723a6f0cc1bdef29b520d0e8f614bcace1668881f7186d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.",
                "category": "company",
                "datetime": 1790081820,
                "headline": "MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going"
              },
              {
                "id": 142337733,
                "url": "https://finnhub.io/api/news?id=ac2334a1ad7d0851eb6c652f776731ce1f86d33abf8f86974e1f9e3fa399b94f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all existing local indications. The new subcutaneous version offers an alternative to intravenous dosing, aimed at faster administration for patients and clinicians. This approval broadens Merck's oncology treatment options in Japan, a key international market for its immunotherapy portfolio. The KEYTRUDA QLEX subcutaneous green light in Japan matters. However, investors...",
                "category": "company",
                "datetime": 1790079266,
                "headline": "Why Is Merck (MRK) In Focus After Japan Cleared A New Dosing Option?"
              },
              {
                "id": 142336239,
                "url": "https://finnhub.io/api/news?id=25a682a003b590ab40e1bf3dccd036cbc19a656aeec301a69a0387eb9fd609fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 22, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signaling inhibitor, is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise",
                "category": "company",
                "datetime": 1790073900,
                "headline": "U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)"
              },
              {
                "id": 142330945,
                "url": "https://finnhub.io/api/news?id=243db43307a3884832bb7a9dcdd2c7dbdfabb3920122c6201283cb5cc65b8c33",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_8_e78aee1045.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Meta's agentic AI assistant Muse lit a fire under tech on Monday, pushing the Nasdaq to a record close and lifting chipmakers by double digits. Cheaper oil, a ten-year yield back below 5% and a friendlier tone between Washington and Beijing did the rest, while Paramount cleared the last big hurdle for its Warner Bros. Discovery takeover.",
                "category": "company",
                "datetime": 1790069368,
                "headline": "Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade"
              },
              {
                "id": 142339080,
                "url": "https://finnhub.io/api/news?id=82b7d157022b5630169a3c29b1368957622755f00d681a354c2ff1f977c7bf48",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "In HYPERION, in patients diagnosed with PAH in the last 12 months, adding WINREVAIR on top of background therapy reduced the risk of clinical worsening events compared to placebo, informing the use of WINREVAIR earlier",
                "category": "company",
                "datetime": 1790059710,
                "headline": "Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial"
              },
              {
                "id": 142340644,
                "url": "https://finnhub.io/api/news?id=033972e3854745199d16a43e53d2bfecd4f709597d776ba31ba77bbd14999b14",
                "image": "https://image.cnbcfm.com/api/v1/image/108264668-1770841844066-gettyimages-2260574499-DOUSTDAR_INTERVIEW.jpeg?v=1770841930&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.",
                "category": "company",
                "datetime": 1790052809,
                "headline": "Novo defends diversification push as CEO eyes deals beyond obesity"
              },
              {
                "id": 142317006,
                "url": "https://finnhub.io/api/news?id=a3772c9db7fa2659e540d9d44603e9d5e45eef8219039632051df3762e5311cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.",
                "category": "company",
                "datetime": 1790035585,
                "headline": "Moderna (MRNA) Stock Trades Up, Here Is Why"
              },
              {
                "id": 142316160,
                "url": "https://finnhub.io/api/news?id=2892f1330a0430b1506a17d5a26c0b373902d857dad5de056751d8d2fa2545d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost",
                "category": "company",
                "datetime": 1790035322,
                "headline": "Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion"
              },
              {
                "id": 142315103,
                "url": "https://finnhub.io/api/news?id=b53529fb4b4e50f832281391ee6152c1bd95ce2d1b0a9963b6ed300a46036f95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones index rallies on the stock market today after Treasury Secretary Scott Bessent touts China talks. Nvidia stock climbs.",
                "category": "company",
                "datetime": 1790019499,
                "headline": "Stock Market Today: Nasdaq Roars As Micron Tests Entry; AMD In Buy Zone As It Eyes New High (Live Coverage)"
              },
              {
                "id": 142315099,
                "url": "https://finnhub.io/api/news?id=6d60da61cbd8368a9385e258e82f236ed4c21589fd290338e6e3784639a7853c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1790017808,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 142314867,
                "url": "https://finnhub.io/api/news?id=75368c5390dea5e6596b02a0e97eee378a8d5acece9df7257ee2b759aa52aba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna will showcase detailed melanoma results for Intismeran at ESMO, alongside data and trial updates exploring the personalized therapy in pancreatic and lung cancers.",
                "category": "company",
                "datetime": 1790012420,
                "headline": "Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’"
              },
              {
                "id": 142315248,
                "url": "https://finnhub.io/api/news?id=9ff8e3b718970a67aaa7be93f9da3163f583126eead130c4faac2462b128879a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.",
                "category": "company",
                "datetime": 1790010720,
                "headline": "Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test."
              },
              {
                "id": 142314740,
                "url": "https://finnhub.io/api/news?id=14e4cf65769e673f42a4d4281a5372e23d98a76970930436984c66e0099204fa",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1790008805,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 142314828,
                "url": "https://finnhub.io/api/news?id=90b2da6f1c010ca0c0afbc6e0da4e706ef8d938405a2b7b029e85696882d9e2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...",
                "category": "company",
                "datetime": 1790006100,
                "headline": "Novo Nordisk shares plunge over 7% as new targets fail to reassure investors"
              },
              {
                "id": 142314336,
                "url": "https://finnhub.io/api/news?id=143bc461be0269bf017118b7f207e3e541e763e93bb2ae7b50d697949e0d2576",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna (NASDAQ:MRNA) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at the European Society for Medical Oncology congress in Madrid. The stock is at $167.90, up 9% in Monday morning […]",
                "category": "company",
                "datetime": 1790005555,
                "headline": "Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher"
              },
              {
                "id": 142314284,
                "url": "https://finnhub.io/api/news?id=178992e42ee9f0c49528335e79204790d9b91e65690094d8cf69c29a9dc072b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth",
                "category": "company",
                "datetime": 1790005510,
                "headline": "Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations"
              },
              {
                "id": 142314337,
                "url": "https://finnhub.io/api/news?id=a3fbb9ef46bd835499e6b944b9d6c76eb9a720dba98e4378c1c04594e545a5b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.",
                "category": "company",
                "datetime": 1790004420,
                "headline": "Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer"
              },
              {
                "id": 142314339,
                "url": "https://finnhub.io/api/news?id=1c0904ab76802c9b01ae07aa5de94000aea4551454466795cfe266ba7dc8cff0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.",
                "category": "company",
                "datetime": 1790004120,
                "headline": "AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies"
              },
              {
                "id": 142314289,
                "url": "https://finnhub.io/api/news?id=43c5b8d478c44c5c601e95e4f5d0e6e83ec991b24d54554113f36b06e5927bc3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.",
                "category": "company",
                "datetime": 1790000231,
                "headline": "What Would It Take For Pfizer To Cut Its Dividend?"
              },
              {
                "id": 142312760,
                "url": "https://finnhub.io/api/news?id=953ccdbbf1c8def93b545aa0b605c74a1651a8d2eb038522527d5747f34bb8ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.",
                "category": "company",
                "datetime": 1789997580,
                "headline": "OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?"
              },
              {
                "id": 142312759,
                "url": "https://finnhub.io/api/news?id=5dc9df571a7417d0022e972f1f9f5e33b96b0b8fc1278142dfe5e63125ccbdf3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is proud to be the presenting partner of Chiharu Shiota: The Soul Trembles, a landmark contemporary art exhibition making its North American premiere at the Montreal Museum of Fine Arts (MMFA) from September 26, 2026, to February 14, 2027.",
                "category": "company",
                "datetime": 1789995600,
                "headline": "Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles"
              },
              {
                "id": 142310717,
                "url": "https://finnhub.io/api/news?id=2094a2c5f9c153b52aeda12f343c88808922fee79702e16bb8ec9cad1deb9cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.",
                "category": "company",
                "datetime": 1789988803,
                "headline": "FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week"
              },
              {
                "id": 142310718,
                "url": "https://finnhub.io/api/news?id=2e2dc8b8630d2e4fc424d6dc045ea31286d575d9f6f77871fafc194275b8f951",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administer",
                "category": "company",
                "datetime": 1789987500,
                "headline": "Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan"
              },
              {
                "id": 142313784,
                "url": "https://finnhub.io/api/news?id=8e49a3f20e0c419042d36d85dbaf1edeadaa9f681cda5a554e03212fd4068aae",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "KEYTRUDA QLEX is the first and only subcutaneous immune checkpoint inhibitor in Japan that can be administered by a healthcare provider in as little as one minuteMerck (NYSE:MRK), known as MSD outside of the United",
                "category": "company",
                "datetime": 1789973275,
                "headline": "Merck's Subcutaneous KEYTRUDA QLEX Approved In Japan For All Existing KEYTRUDA Indications"
              },
              {
                "id": 142340649,
                "url": "https://finnhub.io/api/news?id=2059a9ef57dbfa8b8e82f89f3b9878fe009b8717089366ff4944c7fa9b32ff70",
                "image": "https://image.cnbcfm.com/api/v1/image/108363158-17894901612026-09-15t163359z_2080430281_rc2qjna3z3zx_rtrmadp_0_novo-nordisk-strategy-townhall.jpeg?v=1789490250&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.",
                "category": "company",
                "datetime": 1789964630,
                "headline": "Novo shares slide as drugmaker lays out post-Wegovy growth strategy"
              },
              {
                "id": 142270884,
                "url": "https://finnhub.io/api/news?id=e98d2222337f8cf93a6bce804cfa47868a4b140cc47bd2863da54ef1327015ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's blockbuster momentum.",
                "category": "company",
                "datetime": 1789822538,
                "headline": "Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?"
              },
              {
                "id": 142272069,
                "url": "https://finnhub.io/api/news?id=53c6f69c8b75743ec9a691d1785a5f12386a78695e4bdc7ac4051ab5516225cc",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2286751578/image_2286751578.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Data center construction spending increased nearly 60% YoY in July 2026 to surpass a $75 billion annualized pace as AI translates into a major U.S. construction cycle. Read more here.",
                "category": "company",
                "datetime": 1789818300,
                "headline": "The Next Big Theme: September 2026"
              },
              {
                "id": 142269641,
                "url": "https://finnhub.io/api/news?id=13f780888e8f80a1dd6391f3566fca74c418354f968b1de73cb4854818c0ee6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Investors need something that evolves with a changing economy.",
                "category": "company",
                "datetime": 1789808400,
                "headline": "The S&P 500 Has Returned About 11% Annually Since 1958. Here's the ETF I'd Trust for the Next 30 Years."
              },
              {
                "id": 142265937,
                "url": "https://finnhub.io/api/news?id=b356f0fe197865d9044098d7597c0feaa5c27513b0c969541884a463486bb1c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received a positive opinion from the EMA’s CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The CHMP verdict on KEYTRUDA plus Padcev is only one piece of the wider Merck story...",
                "category": "company",
                "datetime": 1789773124,
                "headline": "What Does Merck (MRK) Mean For EU Bladder Cancer Treatment After CHMP Support?"
              },
              {
                "id": 142261589,
                "url": "https://finnhub.io/api/news?id=54df5f016c8600f13a10888e90e64776abee0241969e28b62d56bf3a39184938",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.",
                "category": "company",
                "datetime": 1789766624,
                "headline": "What Would It Take For Eli Lilly Stock To Keep Climbing?"
              },
              {
                "id": 142261590,
                "url": "https://finnhub.io/api/news?id=6572a5021732f68f24fe85712b975f2685cebd4f425352919f077a9ada7b76ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.",
                "category": "company",
                "datetime": 1789762483,
                "headline": "Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price?"
              },
              {
                "id": 142259470,
                "url": "https://finnhub.io/api/news?id=92f987af62e597d433d764b32bc34040d20ff98a77507c00fc79b26e76a00f4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.",
                "category": "company",
                "datetime": 1789754949,
                "headline": "Merck Stock Nearly Doubled Without A Change In Its Revenue Growth"
              },
              {
                "id": 142259575,
                "url": "https://finnhub.io/api/news?id=41927abf64b55e3d6fa322cce5ffdea667fc15cf1e3377139b330dcaddd04d9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.",
                "category": "company",
                "datetime": 1789744004,
                "headline": "Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?"
              },
              {
                "id": 142271653,
                "url": "https://finnhub.io/api/news?id=367969b74b60b02f14511121e264ddfc432205cc9d02b1c00570ea64f0ea4433",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/18/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.",
                "category": "company",
                "datetime": 1789735540,
                "headline": "Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer"
              },
              {
                "id": 142253956,
                "url": "https://finnhub.io/api/news?id=c70ac689ec1d5fbf3bd1835d178295fa60f9777c84eaaf75f1de1ceabe785eb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.",
                "category": "company",
                "datetime": 1789732832,
                "headline": "5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income"
              },
              {
                "id": 142253040,
                "url": "https://finnhub.io/api/news?id=1e6ea1981304365bbc6bef120b22d938ae20c494bb2c0c0e1048bfd81d585ace",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 18, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invas",
                "category": "company",
                "datetime": 1789728900,
                "headline": "Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)"
              },
              {
                "id": 142253038,
                "url": "https://finnhub.io/api/news?id=2f6eefc13df494060c6ce50adde2fabe5521acb910efd6ab9dd6854fdc97e98f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 18, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today launched Your Hive of Whole Health, a multi-year educational program that helps people living with HIV build personalized networks of support to address their physical, mental, emotional, and social well-being. Unveiled at the 2026 U.S. Conference on HIV/AIDS (USCHA) in Anaheim, California, Sept. 17-20, 2026, the initiative aims to honor the strides made toward ending the epidemic whi",
                "category": "company",
                "datetime": 1789728300,
                "headline": "Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV"
              },
              {
                "id": 142255346,
                "url": "https://finnhub.io/api/news?id=d7987a3ae2b5be3b10e7f5740bb809707d3799bdd637d7bb3695c001cc243347",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1376080885/image_1376080885.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Veradermics (MANE) stock outlook: Phase 3 VDPHL01 readouts, FDA approval odds, cash runway, and hair loss market upside—see the bull case and act now.",
                "category": "company",
                "datetime": 1789724340,
                "headline": "Veradermics: Buy Before The Catalysts"
              },
              {
                "id": 142254787,
                "url": "https://finnhub.io/api/news?id=9e36abb4736760f20f2560d69abeba3d6a402c6a5b6c3ebfc2d1ef95ab93e692",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1630128517/image_1630128517.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.",
                "category": "company",
                "datetime": 1789723352,
                "headline": "5 Undervalued Oncology Stocks Wall Street Is Overlooking"
              },
              {
                "id": 142247153,
                "url": "https://finnhub.io/api/news?id=a86914365c9394419df46d0712d12413f86ea6b753c6add0a2c0f762545692b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.",
                "category": "company",
                "datetime": 1789722240,
                "headline": "BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?"
              },
              {
                "id": 142252319,
                "url": "https://finnhub.io/api/news?id=2a57562e248a903fb341c7a0ca118e325b89de1403bfcc3bbb1a3200545a0235",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201143673/image_2201143673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Schwab US Dividend Equity ETF (SCHD) has outperformed SPY year-to-date, widening its lead during recent market volatility.",
                "category": "company",
                "datetime": 1789716891,
                "headline": "The Hidden Winners Inside SCHD - September 2026"
              },
              {
                "id": 142256138,
                "url": "https://finnhub.io/api/news?id=5a9ee9dfbc34e6b93faab605ac7c6b04667c0c1c4040257c9847db1c593dc9ec",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Opinion granted based on positive results from the Phase 3 KEYNOTE-B15 trial, which demonstrated improvements in event-free survival, overall survival and pathologic complete response rateIf approved, KEYTRUDA plus",
                "category": "company",
                "datetime": 1789714667,
                "headline": "EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer"
              },
              {
                "id": 142233869,
                "url": "https://finnhub.io/api/news?id=5fb9ffd5ba89cfd23cf51fdcef2f1292c4c60707adfdebff107474f4da2ad100",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day.",
                "category": "company",
                "datetime": 1789681804,
                "headline": "Merck (MRK) Outperforms Broader Market: What You Need to Know"
              },
              {
                "id": 142233870,
                "url": "https://finnhub.io/api/news?id=0561b049eec720b2c841091ae001f9aeac9458f1ffa201652518579e2ae67cc7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Commercial orbital laboratories could extend proven microgravity research, but regulation and return logistics remain unresolved.",
                "category": "company",
                "datetime": 1789672694,
                "headline": "Merck Gains as Keytruda's Space Research Seeks a New Home"
              },
              {
                "id": 142232756,
                "url": "https://finnhub.io/api/news?id=42e646b3db8ab4aab5465720745cba226c0c283d0cc8963fdf0343cf6a133d9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.",
                "category": "company",
                "datetime": 1789672646,
                "headline": "Can Volume Keep Covering Eli Lilly's Price Cuts?"
              },
              {
                "id": 142229483,
                "url": "https://finnhub.io/api/news?id=dfb76a66e1436e85948b341453048bdf27d660ffca2da6ee1a728671127df0b6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1789672206,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 142233841,
                "url": "https://finnhub.io/api/news?id=dff84dca4459f176253cc46ad9b7cd937c446900ee8f206ed1548c3699318784",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna President Stephen Hoge says the company remains on track for its longtime goal of reaching cash breakeven by 2028.",
                "category": "company",
                "datetime": 1789662720,
                "headline": "Moderna: Another Day, Another Big Stock Move. Is the Cancer Vaccine Rally Back On?"
              },
              {
                "id": 142225896,
                "url": "https://finnhub.io/api/news?id=4cc8ec4e2e2b9a0be509dcd505099e48738427996e1ae7086a59319906ffad80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.",
                "category": "company",
                "datetime": 1789653031,
                "headline": "Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher"
              },
              {
                "id": 142255517,
                "url": "https://finnhub.io/api/news?id=57103ef2ad5450b5bcaf5a9aaa4e7823c90b0a439f905d8c893ea54581b70091",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/17/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna Inc. (NASDAQ: MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.",
                "category": "company",
                "datetime": 1789650147,
                "headline": "Moderna Stock Is Surging: What's Going On?"
              },
              {
                "id": 142255518,
                "url": "https://finnhub.io/api/news?id=31f452119e13f441da93089d6ea887533c8a4bd58b40f0b5fdf1b87bdc15d54d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/17/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna stock has more than doubled after its cancer-vaccine breakthrough. Now investors face the harder question: Can it become an oncology powerhouse?",
                "category": "company",
                "datetime": 1789649963,
                "headline": "Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part"
              },
              {
                "id": 142223863,
                "url": "https://finnhub.io/api/news?id=dc4cbf8b69fbadfb93aa4d383979cd3fcb3a5cf28f9596c1e165bded9540a7e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.",
                "category": "company",
                "datetime": 1789647089,
                "headline": "What Happens To AbbVie Stock If SKYRIZI Slows Down?"
              },
              {
                "id": 142223864,
                "url": "https://finnhub.io/api/news?id=af7eaaa8344807455788124ff567232d313a78a57bf462a62eaefaee3b4205d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Auxier Asset Management, an investment advisory firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Following a strong rebound from the first-quarter decline, the S&P 500 gained 15.2% as accelerating capital spending toward artificial intelligence infrastructure drove significant gains across technology hardware companies. Semiconductor and data-center-related businesses benefited from supply constraints […]",
                "category": "company",
                "datetime": 1789646258,
                "headline": "Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise"
              },
              {
                "id": 142223777,
                "url": "https://finnhub.io/api/news?id=437e9d4adaeff009193aee00caf8c844c18b27050c61cbcd0f1a1193c1dd7a0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "With $124 trillion set to move in the Great Wealth Transfer, these wealth-building stocks can help you leave something behind for your kids.",
                "category": "company",
                "datetime": 1789639200,
                "headline": "5 Wealth-Building Stocks to Buy With an Inheritance, So You Have Something to Leave Your Kids, Too"
              },
              {
                "id": 142201180,
                "url": "https://finnhub.io/api/news?id=f18ff60a19b03a3e4eb745f510ed74b65c961a3130cc840808d3eb4280fba88d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.",
                "category": "company",
                "datetime": 1789589528,
                "headline": "Is Pfizer's New Business Big Enough To Carry The Old One?"
              },
              {
                "id": 142202479,
                "url": "https://finnhub.io/api/news?id=9ac626cbb3740dc82015a43c1ba5151179f3ac6e119edf815a6b8eeccf08aff7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as Princi",
                "category": "company",
                "datetime": 1789588860,
                "headline": "Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors"
              },
              {
                "id": 142201173,
                "url": "https://finnhub.io/api/news?id=3d0df9ad6ddd2a83bcc97583694630de37cbbdc6c1f7b071f3d62dbe8693fdc7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.",
                "category": "company",
                "datetime": 1789585922,
                "headline": "Should You Judge JNJ Stock Without STELARA?"
              },
              {
                "id": 142202480,
                "url": "https://finnhub.io/api/news?id=85ecfd4abd5ba2a944c4797ae14d753f2036b5f86e23b4c0e96af02d6e0d0861",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The bank's peak sales estimate for laroprovstat sits 30% above consensus",
                "category": "company",
                "datetime": 1789585399,
                "headline": "AstraZeneca Shares Rise as J.P. Morgan Stays Overweight"
              },
              {
                "id": 142202478,
                "url": "https://finnhub.io/api/news?id=9e0b6788ff74b1ee55df818058fde15910b46cb3efa6c4b3e242d3ae115025f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.",
                "category": "company",
                "datetime": 1789563602,
                "headline": "This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%"
              },
              {
                "id": 142228060,
                "url": "https://finnhub.io/api/news?id=074bf9d61dc20208600cd0c33805d738b92f919a156538b41bc03067e8447927",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 3.02% on an annualized basis producing an average annual return of 14.92%. Currently, Merck & Co has a market capitalization of $355.77",
                "category": "company",
                "datetime": 1789561038,
                "headline": "Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years"
              },
              {
                "id": 142196382,
                "url": "https://finnhub.io/api/news?id=dccdcbda79bd8e6c0d6a63c7f53d7dd3bc5ac3fe3f8424a34b4f440e7cddc050",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/16/Anthropic-Logo-Is-Displayed-On-The-Scree.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement responsible data governance standards.",
                "category": "company",
                "datetime": 1789555460,
                "headline": "Novo Nordisk, Anthropic Team Up For AI Drug Research"
              },
              {
                "id": 142174545,
                "url": "https://finnhub.io/api/news?id=2f3cd639a406977373ccb2afa7762a39e1fcaaedd1238de65ada8bb49104f49b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In early September 2026, Merck & Co., Inc. deepened its innovation push through multiple investor conferences and a new clinical trial collaboration in which Perspective Therapeutics announced it will test its targeted alpha therapy [212Pb]PSV359 with Merck’s immunotherapy Keytruda in certain FAP-a–expressing lung and colorectal cancers. At the same time, Merck partnered with The Hashgraph Group and PwC Germany on a cocoa traceability pilot that links its M-Trust physical authentication...",
                "category": "company",
                "datetime": 1789524741,
                "headline": "Oncology Tie-Up and Blockchain Pilot Might Change The Case For Investing In Merck (MRK)"
              },
              {
                "id": 142172297,
                "url": "https://finnhub.io/api/news?id=bd676c4b44a7da2d7f11725925ca1f235568cd8910e075fe2bc5a17b09e1dee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.",
                "category": "company",
                "datetime": 1789519473,
                "headline": "Merck Stock: Is The $70 Billion Pipeline Worth the Premium?"
              },
              {
                "id": 142167114,
                "url": "https://finnhub.io/api/news?id=a2fd6ceef859ea3281feda9ce6737beeb691937977ad1252cfc372c6ed60226b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Tuesday.",
                "category": "company",
                "datetime": 1789499406,
                "headline": "Discover which dow jones stocks are making waves on Tuesday."
              },
              {
                "id": 142165601,
                "url": "https://finnhub.io/api/news?id=fb42255126a572d81f834bf8bbfd884e039725d517b0f087b8ca45a58f310ec8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?",
                "category": "company",
                "datetime": 1789489440,
                "headline": "Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?"
              },
              {
                "id": 142165598,
                "url": "https://finnhub.io/api/news?id=ab0ee2779fab20c3be5879dcb9c1d9689c31db19741d4f93305c89265a9ee455",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.",
                "category": "company",
                "datetime": 1789485720,
                "headline": "Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study"
              },
              {
                "id": 142165473,
                "url": "https://finnhub.io/api/news?id=3563b4f01ddf6785f748d560a36fd080f37613a38ffbf4bf80a2d6bd2a9e11f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head of Development Operations. Dr. Koblan is a biopharmaceutical R&D leader with more than 30 years […] The post Slate Medicines Names Kenneth Koblan as Chief Scientific Officer appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1789485488,
                "headline": "Slate Medicines Names Kenneth Koblan as Chief Scientific Officer"
              },
              {
                "id": 142160599,
                "url": "https://finnhub.io/api/news?id=fd4c36202cfbc10dc7a2bb166c134d69ec4c5aa2740a8311da4dd6c82b5ec25f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be sharper. One company is compounding a franchise that keeps widening, while the other is racing to patch a hole before a patent cliff arrives.",
                "category": "company",
                "datetime": 1789475457,
                "headline": "Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030"
              },
              {
                "id": 142160598,
                "url": "https://finnhub.io/api/news?id=f58427fbb86036580774f4641ae6f2b119b5f89a1233273939320578dde7c906",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co Inc (NYSE:MRK) recently announced a total dividend of $0.85 per share, with the ex-dividend date set for 2026-09-15.  This amount includes a $0.85 per share cash dividend payable on 2026-10-07.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.",
                "category": "company",
                "datetime": 1789470052,
                "headline": "Merck & Co Inc's Dividend Analysis"
              },
              {
                "id": 142159885,
                "url": "https://finnhub.io/api/news?id=a4b46ca11ba1df1e61e495b10b1ea46d00ddcfd3359d9b753f08cdbbea0b3313",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple mye",
                "category": "company",
                "datetime": 1789469748,
                "headline": "GSK to Acquire Experimental Blood Cancer Therapy From Chimagen in $750 Million Deal"
              },
              {
                "id": 142161114,
                "url": "https://finnhub.io/api/news?id=e0a46a3e96468ef723c9a6e0edd34b14e767d139d358c14664cddee9ab91f2f8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1534372283/image_1534372283.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Retirement income update: Why the 4% rule can fail in today’s market and how a yield-first ETF mix may pay ~$48k/$1M. Read the full analysis here.",
                "category": "company",
                "datetime": 1789463700,
                "headline": "These 3 Income-Oriented ETFs Are All You Need For Retirement"
              },
              {
                "id": 142141460,
                "url": "https://finnhub.io/api/news?id=3a98044ac4b6f23324733bc692e4fbca42478e8581ca190c1e30e51b81227480",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its Animal Health segment during a Morgan Stanley discussion. Davis said recent pipeline readouts ha",
                "category": "company",
                "datetime": 1789419729,
                "headline": "Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation"
              },
              {
                "id": 142141404,
                "url": "https://finnhub.io/api/news?id=8c494d4ac5e9ac11fcd75585131b88ccfa256a59f93e100ba24e82a5497f2c62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.",
                "category": "company",
                "datetime": 1789416562,
                "headline": "Is This LLY Stock Dip Big Enough To Be Worth Buying?"
              },
              {
                "id": 142141406,
                "url": "https://finnhub.io/api/news?id=e37148134b2f7452c0ceaaf02e895b7442ec37c6357e70dadd2e0a83cc3eb9db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.",
                "category": "company",
                "datetime": 1789415853,
                "headline": "Why Is Pfizer Stock Paying You So Much To Wait?"
              },
              {
                "id": 142140981,
                "url": "https://finnhub.io/api/news?id=c1d61606a2b029ce668dcd95132b985fd049fae9477039860e7e3d20d74b2dd2",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (MRK) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 3:20 PM EDTCompany ParticipantsRobert Davis -...",
                "category": "company",
                "datetime": 1789405303,
                "headline": "Merck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142141463,
                "url": "https://finnhub.io/api/news?id=2d9215ca0e51fb12ba542972bc9f33ca9a5cf90c194d430c5424b7ceabb7895b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.",
                "category": "company",
                "datetime": 1789404060,
                "headline": "Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results"
              },
              {
                "id": 142163124,
                "url": "https://finnhub.io/api/news?id=b6f85b752aef9b69958c6101ba22641d7b270cfe69c3da5c559e93c7f96106c9",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.merck.com/events/morgan-stanley-24th-annual-global-healthcare-conference/",
                "category": "company",
                "datetime": 1789400867,
                "headline": "Merck & Co Exec Says Timing For Raising The $70B Forecast Is \"To Be Determined\" Adds \"It's Coming\""
              },
              {
                "id": 142163125,
                "url": "https://finnhub.io/api/news?id=6563066a9db9e28a32391e29a48ab53df5d48b81127ed37849169f9bc8e700e7",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.merck.com/events/morgan-stanley-24th-annual-global-healthcare-conference/",
                "category": "company",
                "datetime": 1789400106,
                "headline": "Merck Exec Speaking At Morgan Stanley Conference Says Potential 340B And Policy Changes Would Create Tailwinds But Are Not Material To The Business"
              },
              {
                "id": 142139343,
                "url": "https://finnhub.io/api/news?id=0051af0c446280a7c64c3bc8d728f7e2d68324651c5be67800137b14b8af9ca0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types. Speaking at a Morgan Stanley ev",
                "category": "company",
                "datetime": 1789398166,
                "headline": "Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types"
              },
              {
                "id": 142139344,
                "url": "https://finnhub.io/api/news?id=f88f51a1b471a26fa335e9a3fce13008f06656b23ab193a54e6535808c4bc352",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.",
                "category": "company",
                "datetime": 1789395120,
                "headline": "Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?"
              },
              {
                "id": 142137143,
                "url": "https://finnhub.io/api/news?id=ac49d39d7e79e9a08966ea7bdb0e332e0d2d4347ea105ca309a46acf0bc18cb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.",
                "category": "company",
                "datetime": 1789393020,
                "headline": "Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?"
              },
              {
                "id": 142137177,
                "url": "https://finnhub.io/api/news?id=7bc4aea4ec95b56bd0f34332108b1457a014059262be4c7e516885fac8e0c08f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.",
                "category": "company",
                "datetime": 1789391100,
                "headline": "BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors"
              },
              {
                "id": 142135935,
                "url": "https://finnhub.io/api/news?id=574d3d3cf76dc486c467fa67d6d8f85d06c877a024adc4319303e632d0401400",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears in a stock this dominant.",
                "category": "company",
                "datetime": 1789383717,
                "headline": "Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve"
              },
              {
                "id": 142136270,
                "url": "https://finnhub.io/api/news?id=1a4c182b8ed51bd39602a5c163e67689dd86856f61761214143da26bbd4cbbf8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com",
                "category": "company",
                "datetime": 1789380960,
                "headline": "Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors"
              },
              {
                "id": 142137435,
                "url": "https://finnhub.io/api/news?id=3dd03c51b5dd7f67466aa620fd75514400c012af0532e1982cd913095540afbb",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for",
                "category": "company",
                "datetime": 1789366753,
                "headline": "Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer"
              },
              {
                "id": 142115572,
                "url": "https://finnhub.io/api/news?id=a0a0c5887cf26ad9f04706d689434f4bbd8bd42a5fb64d97f2be4bb30f8e0347",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Discussing his fantasy roster on the September 8 episode of Mad Money, Jim Cramer turned his focus to pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) to support his defense and special teams unit, as he remarked: Beyond the offense, there’s a spot on your roster for something called a defense/special teams pick in fantasy football. […]",
                "category": "company",
                "datetime": 1789231751,
                "headline": "Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock"
              },
              {
                "id": 142103408,
                "url": "https://finnhub.io/api/news?id=56ae7e2994a1aa020f1180a1c47eb43cd63e63717d394d4e9bc383a6fdd81b12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Income seekers can't go wrong with these companies.",
                "category": "company",
                "datetime": 1789197602,
                "headline": "2 Outstanding Dividend Stocks to Buy and Hold for 10 Years"
              },
              {
                "id": 142089433,
                "url": "https://finnhub.io/api/news?id=4ae9498ecd56e299779ddffb0f6ac4ad216aa14954b49be19d26f04673465af6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.",
                "category": "company",
                "datetime": 1789153872,
                "headline": "Is AbbVie Stock Actually Overpriced?"
              },
              {
                "id": 142089166,
                "url": "https://finnhub.io/api/news?id=d203da3fbc27c56f1bb176547ad99ad90d3267147090af2aa48d0f2d8febe0d4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1789153805,
                "headline": "Friday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142091220,
                "url": "https://finnhub.io/api/news?id=3b25c7758098d2e2e83b4a3df7b4ca76db0ada28ba2f63fcd051f9886485f820",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Read this week's dividend recap for Dividend Champions, Contenders & Challengers—track dividend changes, upcoming ex-dividend dates & pay dates.",
                "category": "company",
                "datetime": 1789150194,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week September 13"
              },
              {
                "id": 142087444,
                "url": "https://finnhub.io/api/news?id=9c28e90ce88d4870a13d7df5c21ab3737a9c3b83bc9b726f65702c45b7892fde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.",
                "category": "company",
                "datetime": 1789142190,
                "headline": "Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat"
              },
              {
                "id": 142087095,
                "url": "https://finnhub.io/api/news?id=3f68237b52bc07ee41445a0243eb8e461258e10ef1e9fda3f64a0a23ece2ee75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.",
                "category": "company",
                "datetime": 1789139820,
                "headline": "MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE"
              },
              {
                "id": 142088208,
                "url": "https://finnhub.io/api/news?id=f6029aba4873dea296c598d1e5fe204dde17d8a51b84a48dc73af2405cc06827",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214872699/image_2214872699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "IHE trades at a P/E of 16.11x and is rated HOLD due to regulatory, patent, and concentration risks. Click for more details on the IHE fund.",
                "category": "company",
                "datetime": 1789134884,
                "headline": "IHE: Innovation Supports The Outlook, Valuation Limits Conviction"
              },
              {
                "id": 142077790,
                "url": "https://finnhub.io/api/news?id=5438e621f219194baa1d15e7fcb042fb457a38175e06217a807e7539eaec7fc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The global Advanced Bioreactor Systems Market is projected to grow from USD 4.2 billion in 2026 to USD 11.8 billion by 2036, at a CAGR of 10.9%. Growth is driven by biologics manufacturing, cell and gene therapies, single-use bioreactors, continuous bioprocessing, and AI-based process control. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes market segments, regional opportunities, technology trends, and key companies including Sartorius, Thermo",
                "category": "company",
                "datetime": 1789114140,
                "headline": "Advanced Bioreactor Systems Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)"
              },
              {
                "id": 142069657,
                "url": "https://finnhub.io/api/news?id=6fd4ed7ef8b3e9bca9664e21c8781567191fc9e2f696875c351e61b029718f21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking",
                "category": "company",
                "datetime": 1789102925,
                "headline": "OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months"
              },
              {
                "id": 142086503,
                "url": "https://finnhub.io/api/news?id=e628c29605c5f0847b5aef56a86ce8a16d5789c9f8ef65443d363904182bc5ce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/11/Number-Of-Cigarettes-Isolated-Tobacco-Da.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.",
                "category": "company",
                "datetime": 1789097046,
                "headline": "Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food"
              },
              {
                "id": 142084622,
                "url": "https://finnhub.io/api/news?id=bff5c63cfc5c920d7d97d937d7cd2e5feba7c372ce8f53a88d435e2f2d16f32a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.",
                "category": "company",
                "datetime": 1789092119,
                "headline": "Merck builds around Keytruda; prediction markets raise new risks"
              },
              {
                "id": 142066203,
                "url": "https://finnhub.io/api/news?id=82d4994d91fdd80a460935678d97a2d7176f3832d1c607a4401e58380e9be46f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the most recent trading session, Merck (MRK) closed at $144.71, indicating a -1.91% shift from the previous trading day.",
                "category": "company",
                "datetime": 1789077004,
                "headline": "Merck (MRK) Dips More Than Broader Market: What You Should Know"
              },
              {
                "id": 142064745,
                "url": "https://finnhub.io/api/news?id=ec7e31288ec30d3ed445c243aaa5470eb1ec4dfe7aa9137eda86ec50309ce44d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.",
                "category": "company",
                "datetime": 1789067434,
                "headline": "Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?"
              },
              {
                "id": 142064394,
                "url": "https://finnhub.io/api/news?id=adf9fabb65fa1bdc0746c8cf7941b566bd25d62715d8b6fa00e9d6a2953470bc",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1789067407,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 142087559,
                "url": "https://finnhub.io/api/news?id=096f9fb5e11585c4891fb481b7935b7615675089c0619c2eec382b3910cf138b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/10/Buffett-Musk-Shutterstock.png?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "A congresswoman recently bought stocks connected to Warren Buffett and Elon Musk.",
                "category": "company",
                "datetime": 1789067034,
                "headline": "Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions"
              },
              {
                "id": 142064746,
                "url": "https://finnhub.io/api/news?id=1abe8e7dab24ae7989315403c7be9a89f24836f0d543d8d14ac5a49793d3b96e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.",
                "category": "company",
                "datetime": 1789063054,
                "headline": "JNJ Stock: Is the Rally Running Out of Steam?"
              },
              {
                "id": 142063291,
                "url": "https://finnhub.io/api/news?id=45a4c767641875677341490c5c57df95988778e7db0af9183d8a84bc58b8398b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.",
                "category": "company",
                "datetime": 1789059954,
                "headline": "Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?"
              },
              {
                "id": 142062621,
                "url": "https://finnhub.io/api/news?id=3c6dd7e37edbe2d02b33bc261a6730d798fa99bd613b91d01d5e24dda6b86b3d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Thursday.",
                "category": "company",
                "datetime": 1789058407,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 142063283,
                "url": "https://finnhub.io/api/news?id=65f0ac67eae27fb2191dd56e7eb745fccf116fdc0af9a920181fbeed1f583b13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.",
                "category": "company",
                "datetime": 1789058116,
                "headline": "Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?"
              },
              {
                "id": 142061927,
                "url": "https://finnhub.io/api/news?id=77708395cb873f8e8de1feb66a6d4b96bea1392d39ff1c5ec9ba92ca08be0a88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.",
                "category": "company",
                "datetime": 1789054500,
                "headline": "GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff"
              },
              {
                "id": 142061785,
                "url": "https://finnhub.io/api/news?id=319f28aeaea63b63ec1d3933aeb670aebb9c5465de023eaec04e187f46e57e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.",
                "category": "company",
                "datetime": 1789052702,
                "headline": "Why Has AbbVie Gone Quiet About Humira?"
              },
              {
                "id": 142061929,
                "url": "https://finnhub.io/api/news?id=43458b60b2e94321812dc11320e682a658d20671e047fdbb7076f0a930b46488",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.",
                "category": "company",
                "datetime": 1789052580,
                "headline": "Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?"
              },
              {
                "id": 142063327,
                "url": "https://finnhub.io/api/news?id=d04a62e1ad2172459477f0d878262bfbf3b2b6a32affc0ad595cc90ca30776ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Health policy analysts are raising concerns about the rising cost of Medicare’s prescription drug program after more than 1 in 5 Medicare Part D enrollees hit the program’s $2,000 out-of-pocket drug cap in 2025. The finding, included in a report...",
                "category": "company",
                "datetime": 1789052438,
                "headline": "Medicare’s $2,000 Drug Cap Is Getting Expensive — More Than 1 in 5 Seniors Hit It as Drug Spending Heads Toward $346 Billion"
              },
              {
                "id": 142060792,
                "url": "https://finnhub.io/api/news?id=729954b3edddc9fa048f800ac7f49b5c1f712ff9ba32babbdb9b5a5c7768a621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1789045205,
                "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142059579,
                "url": "https://finnhub.io/api/news?id=a6c317b3e460abcacb3902f7a31911d01e805adf26ba1281143dd2267c765d58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The role will focus on identifying new opportunities and strengthening existing customer relationships to accelerate Ritedose’s continued growthCOLUMBIA, S.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose), the largest contract development and manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit-dose solutions for the ophthalmic and respiratory markets, today announced the appointment of Carolyn Berg as th",
                "category": "company",
                "datetime": 1789040220,
                "headline": "Ritedose Appoints Carolyn Berg as New Vice President of Strategic Growth"
              },
              {
                "id": 142062544,
                "url": "https://finnhub.io/api/news?id=c635754bf641453601db306335d6d6ee43a95105341bf85ef2a6fb7d0e02b5e3",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "September 9, 2026 records indicate that Representative Maria Elvira Salazar filed a purchase of Merck & Co (NYSE:MRK), valued between $34,006 and $160,000. According to the September filing, the transaction occurred",
                "category": "company",
                "datetime": 1789038030,
                "headline": "Recent Filing Shows That Rep. Maria Elvira Salazar Bought Over $34K Worth of Merck & Co Stock"
              },
              {
                "id": 142062545,
                "url": "https://finnhub.io/api/news?id=d93413a0c15fc691f6abcde0de8ab19811061780ea28c87ce78c53cbf316f4dc",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $150 to $172.",
                "category": "company",
                "datetime": 1789033321,
                "headline": "HSBC Maintains Buy on Merck & Co, Raises Price Target to $172"
              },
              {
                "id": 142060793,
                "url": "https://finnhub.io/api/news?id=501b1bfa2a396fea7bf6a4009d23874fce74b44d31e36558453bdad953889fd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.",
                "category": "company",
                "datetime": 1789031853,
                "headline": "mRNA cancer vaccines’ biggest barriers to market"
              },
              {
                "id": 142048468,
                "url": "https://finnhub.io/api/news?id=5915846a89f7a05f7e6ee9b7116407801a68d45a437cbe7d6a367e938e0e0033",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) executives outlined a strategy centered on pipeline investment, new product launches and targeted business development as the company prepares for the eventual loss of exclusivity for KEYTRUDA. Chief Financial Officer Caroline Litchfield said Merck has increased its est",
                "category": "company",
                "datetime": 1789027324,
                "headline": "Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss"
              },
              {
                "id": 142048040,
                "url": "https://finnhub.io/api/news?id=52562ddf2a6c2687841344a20584b7dbbff017f24bdf5eb5c9ae273fdb14f613",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221231962/image_2221231962.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating.",
                "category": "company",
                "datetime": 1789012200,
                "headline": "AI And Robotics In 2026: 16 Recent Developments For Investors"
              },
              {
                "id": 142037821,
                "url": "https://finnhub.io/api/news?id=111db1e73b95e44821420ce4a7307dd477cbd22ec124737b00e8ef9d99e156e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.",
                "category": "company",
                "datetime": 1789007538,
                "headline": "Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes"
              },
              {
                "id": 142029776,
                "url": "https://finnhub.io/api/news?id=d0731908caf2bd1afebdf178ac483ad1e6acebd96431ddace79e6a6f8dcaac48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.",
                "category": "company",
                "datetime": 1788986503,
                "headline": "What Eli Lilly Was Telling You While It Rationed Its Own Launches"
              },
              {
                "id": 142029535,
                "url": "https://finnhub.io/api/news?id=ab9f063581451abab226bae361bb571608d0d3d60f3a1cb25b6582f0302750a7",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (MRK) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsCaroline Litchfield - Executive...",
                "category": "company",
                "datetime": 1788974228,
                "headline": "Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142025946,
                "url": "https://finnhub.io/api/news?id=260787e40763554b599e538d2925e0226176405665e413d8226053bb7d1fd260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Oracle, Merck and Union Pacific headline fresh research, while microcaps CVD Equipment and Koil Energy show strong gains with distinct growth drivers.",
                "category": "company",
                "datetime": 1788964020,
                "headline": "The Zacks Analyst Blog Highlights Oracle, Merck, Union Pacific, CVD Equipment and Koil Energy Solutions"
              },
              {
                "id": 142026820,
                "url": "https://finnhub.io/api/news?id=8b0260feb9fcb3d808bd80def718c92efdb6b0332525b5c181772180baf2e750",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404205960/image_1404205960.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.",
                "category": "company",
                "datetime": 1788959272,
                "headline": "Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up"
              },
              {
                "id": 142027129,
                "url": "https://finnhub.io/api/news?id=7b9872d99f13714aa23da2aa9888679c965f6cc269ca51eaa5b0c87740cf38f6",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Leerink Partners  analyst Daina Graybosch   maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $127 to $161.",
                "category": "company",
                "datetime": 1788955381,
                "headline": "Leerink Partners Maintains Outperform on Merck & Co, Raises Price Target to $161"
              },
              {
                "id": 142025945,
                "url": "https://finnhub.io/api/news?id=8e32170639ff0e7bd3b839b8b729b6dbc8c91ba80384cf5c81997119737f02f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff.",
                "category": "company",
                "datetime": 1788947324,
                "headline": "Merck pairs ADCs with Keytruda in women’s cancer push"
              },
              {
                "id": 141991628,
                "url": "https://finnhub.io/api/news?id=b0c60380221bf68b6b62d8e0691fda4ba0456fc7e91bb5fbf67c3d0df07368f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "178-Page Report Tracks Merck's Cidara Buyout and CD388's Phase 3 Launch as Roche, Moderna, and GSK Compete Beyond the Vaccine Status QuoDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The \"Influenza a Infections - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. A new \"Influenza A - Market Insights, Epidemiology, and Market Forecast - 2036\" report provides a comprehensive analysis of the Influenza A market across the United States, EU4 cou",
                "category": "company",
                "datetime": 1788941220,
                "headline": "Influenza A Market Insight, Epidemiology, and Market Forecast - 2036 Now Available — See Why a 70% Vaccine Failure Rate Is Fueling the Race for Next-Gen Flu Therapies"
              },
              {
                "id": 142023862,
                "url": "https://finnhub.io/api/news?id=11fd80725570f8c725693b9b19b81a17ee99e6102f0085df9eb27e7c4d33d9cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.",
                "category": "company",
                "datetime": 1788937200,
                "headline": "A new immuno-oncology play raises $225M for a next-generation drug"
              },
              {
                "id": 141956234,
                "url": "https://finnhub.io/api/news?id=2a1a523fa8cdd81f0e5a709a42b251d610672c211deec6586755e1992960d0f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Oracle, Merck and Union Pacific lead today's stock reports, with cloud growth, drug sales and rail strength driving their investment stories.",
                "category": "company",
                "datetime": 1788909180,
                "headline": "Top Stock Reports for Oracle, Merck & Union Pacific"
              },
              {
                "id": 141958756,
                "url": "https://finnhub.io/api/news?id=aa5a8dae82f13a09da7b7747ff3e432b7d63e751a7aae9c5efd207e98bc27ce7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788900913,
                "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2026 Update"
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 142025247,
                "url": "https://finnhub.io/api/news?id=8987b9aafbb61dc6d9ec52cbf383b6c49aa3d2df3eb7ee6b70cb6a541d1025c7",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-permanent-roles",
                "category": "company",
                "datetime": 1788884454,
                "headline": "'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg"
              },
              {
                "id": 141950162,
                "url": "https://finnhub.io/api/news?id=70423431bc7b150e3630ade48f615f5dd07d0c36f4e85b7c28b19b44f9016e98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.",
                "category": "company",
                "datetime": 1788878400,
                "headline": "MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 141950156,
                "url": "https://finnhub.io/api/news?id=42df889edd57ef233368d6f8698eadbc5aa569a477a9fd479aacbb24ee6aec58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.",
                "category": "company",
                "datetime": 1788871080,
                "headline": "Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?"
              },
              {
                "id": 141950157,
                "url": "https://finnhub.io/api/news?id=7818a94b5d1882d790a212e39790daa1ada2f2888ae4c8de1c6bc22fa2dafa8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director. Dr. Cannon brings more than 30 years of commercial leadership experience in the biopharmaceutical industry, particularly at Merck and Roivant Sciences. During more than 25 years at Merck, she held senior commercial roles including Global Com",
                "category": "company",
                "datetime": 1788868800,
                "headline": "Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director"
              },
              {
                "id": 141953315,
                "url": "https://finnhub.io/api/news?id=2356be14a57c01489021eb545d17f19625904eb61bcb0c3e797acc2312a23418",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Cancer---Heart-Shape-To-Represent-Medica.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.",
                "category": "company",
                "datetime": 1788866963,
                "headline": "Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates"
              },
              {
                "id": 141951906,
                "url": "https://finnhub.io/api/news?id=8516a4e5e27068b7c69780eccea33f98d398d6703fa4e598ec89e1e4baf85c7b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Eli-Lilly-And-Company-Logo-On-Dark-Backg.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.",
                "category": "company",
                "datetime": 1788866855,
                "headline": "Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back"
              },
              {
                "id": 141950158,
                "url": "https://finnhub.io/api/news?id=423cc2edb18f28a7cfc21f733c16c3c06840dfad2096212e99763a4d877922bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 08, 2026--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference",
                "category": "company",
                "datetime": 1788864300,
                "headline": "Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference"
              },
              {
                "id": 141949322,
                "url": "https://finnhub.io/api/news?id=4327394c95660a20d019c67d42085de8642f275075d61e1337f760a5b7bc2062",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merck’s Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.",
                "category": "company",
                "datetime": 1788862119,
                "headline": "NewAmsterdam Pharma: Potential Coupled With Uncertainty"
              },
              {
                "id": 141954354,
                "url": "https://finnhub.io/api/news?id=819a92d997994b630d6e33f8f6bec3304ec52174db4a013ccf3cb1a51538a42b",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $146 to $170.",
                "category": "company",
                "datetime": 1788860314,
                "headline": "Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $170"
              },
              {
                "id": 141868205,
                "url": "https://finnhub.io/api/news?id=fcfa5e246cc835c64f0d7b5ddb14a2a1a880c36572c3dc06c22aeb5a62e5d566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by ri",
                "category": "company",
                "datetime": 1788856260,
                "headline": "Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio"
              },
              {
                "id": 141950160,
                "url": "https://finnhub.io/api/news?id=ed6e379c5f72322b5d9d309f96e6f633a8dde6088c2625b5e625dd5510bf205f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Hashgraph Group (THG) and science and technology company Merck, are piloting a cocoa traceability solution, with PwC Germany providing consulting and implementation support. The solution connects physical product authentication with blockchain-based digital records and enterprise process design.",
                "category": "company",
                "datetime": 1788850800,
                "headline": "The Hashgraph Group and Merck with support from PwC Germany develop solution for cocoa traceability and digital product passports"
              },
              {
                "id": 141787034,
                "url": "https://finnhub.io/api/news?id=28056929daf7e863fdaa2b0207034941eafc3b574c601e0a07547ac1dadb006a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.",
                "category": "company",
                "datetime": 1788832154,
                "headline": "The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI"
              },
              {
                "id": 141771129,
                "url": "https://finnhub.io/api/news?id=8d4ddd4505d0a2c0a565fc6aa50cad54667e4793873643445d02cbd7344ed953",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.",
                "category": "company",
                "datetime": 1788800445,
                "headline": "Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now"
              },
              {
                "id": 141771109,
                "url": "https://finnhub.io/api/news?id=29beab0809a7c2bc4164cb099588839029845495068a3c91385c65a59211c3d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.New York, USA, Sept. 07, 2026 (GLOBE",
                "category": "company",
                "datetime": 1788800400,
                "headline": "Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight"
              },
              {
                "id": 141760935,
                "url": "https://finnhub.io/api/news?id=9f51313c5b3c77384d06c621b598127ced700b1ca8ebed5cb5ba133ec949c83a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035\" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans",
                "category": "company",
                "datetime": 1788778920,
                "headline": "Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva"
              },
              {
                "id": 141762536,
                "url": "https://finnhub.io/api/news?id=755171ce4130cab475d6d9e4eb412f6569c568e60203dffab6ff579c86acade5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.",
                "category": "company",
                "datetime": 1788699000,
                "headline": "Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It"
              },
              {
                "id": 141491619,
                "url": "https://finnhub.io/api/news?id=c3748497894521a11c661f28144f376bd12e723c1080964e7ff112ad03c70ae4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391545555/image_1391545555.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "With the lagging performance aside, there have been some notable big winners among the index's 30 components. Read more here.",
                "category": "company",
                "datetime": 1788568200,
                "headline": "Nike: Just Not Doing It"
              },
              {
                "id": 141464532,
                "url": "https://finnhub.io/api/news?id=859ae5880b7c332a700086755ffd836f615a8ae3befc592be9cb64449c091135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.",
                "category": "company",
                "datetime": 1788558302,
                "headline": "Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 141452825,
                "url": "https://finnhub.io/api/news?id=112e1e8978d52d2cbd5db13911f01181162e86289295dc3706f8a282f6894de5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1788549006,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141532987,
                "url": "https://finnhub.io/api/news?id=0b2e80aba0b3d7d5fe39a3ddb8053ff207155ae9867f3aa9a29972071b2862fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.",
                "category": "company",
                "datetime": 1788542100,
                "headline": "Revolution Medicines Got Its Breakthrough—What Moves It Next?"
              },
              {
                "id": 141444057,
                "url": "https://finnhub.io/api/news?id=b7fbc72be00a293e3df05b3d90005d43560f1c1c155fdf0a63c6ff2f0f514209",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare...",
                "category": "company",
                "datetime": 1788541761,
                "headline": "Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?"
              },
              {
                "id": 141444058,
                "url": "https://finnhub.io/api/news?id=905919b186b2cb70f624aa1750860bd8a239d54c5d4daa0db9581cc8254fae21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.",
                "category": "company",
                "datetime": 1788541047,
                "headline": "Was JNJ Stock Rally Actually Its Own?"
              },
              {
                "id": 141437305,
                "url": "https://finnhub.io/api/news?id=0c93ddd9be3d327abe99db231fe5877cde8ee6c7727910681b0e469d3573b4d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.",
                "category": "company",
                "datetime": 1788532620,
                "headline": "SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China"
              },
              {
                "id": 141446169,
                "url": "https://finnhub.io/api/news?id=a28c7b57bba478810aa433755c68562b12542576c05229386dec146815ecae11",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $170.",
                "category": "company",
                "datetime": 1788517672,
                "headline": "Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170"
              },
              {
                "id": 141405291,
                "url": "https://finnhub.io/api/news?id=8c38270c7e5423e3afbf1e2a7d23c244a349d8d8d10eff1cc1f97e9ecfaceee5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.",
                "category": "company",
                "datetime": 1788470854,
                "headline": "Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning"
              },
              {
                "id": 141405292,
                "url": "https://finnhub.io/api/news?id=21cfe36b3ec755a99e784bc55dd2dcc02a60b56fc6f524b5661bee05417821eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "LAKE ZURICH, Ill., September 03, 2026--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026.",
                "category": "company",
                "datetime": 1788469200,
                "headline": "Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S."
              },
              {
                "id": 141403790,
                "url": "https://finnhub.io/api/news?id=1548687fecf537e8e4484d6edea21ed97a99feddaf4fd5587f4cad353faadd83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.",
                "category": "company",
                "datetime": 1788457140,
                "headline": "Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense"
              },
              {
                "id": 141402789,
                "url": "https://finnhub.io/api/news?id=fe73ec7a4abefa0321761190f458da536ef1723709c1600d1270ee69f26c1e56",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.",
                "category": "company",
                "datetime": 1788456587,
                "headline": "Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold"
              },
              {
                "id": 141401625,
                "url": "https://finnhub.io/api/news?id=7f9aedd8a41fb14ffcc587468eac74b7ff6e8786ce888f5fb9c434afbabf0e5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.",
                "category": "company",
                "datetime": 1788456240,
                "headline": "Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141401623,
                "url": "https://finnhub.io/api/news?id=571938922c53a24695a79bd4b7bcf6cadc277e382964d905e6dd29c162da8113",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.",
                "category": "company",
                "datetime": 1788454800,
                "headline": "Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141400382,
                "url": "https://finnhub.io/api/news?id=8705547ad79d5ce30f69edff8b117985fe7193bc87ac7ad4d4573de2ed3766c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449419,
                "headline": "Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?"
              },
              {
                "id": 141400340,
                "url": "https://finnhub.io/api/news?id=d605837c09a466bf298019b4b1f79af8743705ece69897637d710b520f1b2b7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.",
                "category": "company",
                "datetime": 1788449092,
                "headline": "Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?"
              },
              {
                "id": 141400381,
                "url": "https://finnhub.io/api/news?id=adeb5e4b160bfa4c1f7b5e497c2d42856d151be4b132e391f5aa87e4415edece",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.",
                "category": "company",
                "datetime": 1788448560,
                "headline": "Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop"
              },
              {
                "id": 141400341,
                "url": "https://finnhub.io/api/news?id=ad022e5bc8dde3e4d944411bba52005d8a98c7c6847a875884ffee4bfc31fea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.",
                "category": "company",
                "datetime": 1788448140,
                "headline": "Pfizer's Pipeline Strategy Centers on Obesity and Oncology"
              },
              {
                "id": 141403192,
                "url": "https://finnhub.io/api/news?id=222861cbe182e09bd124e5448a1086f89de7650eb4bc2e208436fb5e5363a845",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193840462/image_2193840462.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.",
                "category": "company",
                "datetime": 1788444600,
                "headline": "Why Moderna's Cancer Vaccine Matters To Investors"
              },
              {
                "id": 141401187,
                "url": "https://finnhub.io/api/news?id=cc8b651391ba31db3beab971f70b7bb7d2b28c96e9c54b76c55af30bb5547411",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/03/Konskie--Poland---December-08--2024-Summ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase 3 lung cancer clinical trial.",
                "category": "company",
                "datetime": 1788433026,
                "headline": "Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study"
              },
              {
                "id": 141399389,
                "url": "https://finnhub.io/api/news?id=f0ccdd9d70fd4474d7861c8c66dc4fe0a697763c33789ba486aea54f04403eeb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310557609/image_1310557609.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.",
                "category": "company",
                "datetime": 1788429250,
                "headline": "ImmunityBio: None Of The Moonshots Is Priced In"
              },
              {
                "id": 141397497,
                "url": "https://finnhub.io/api/news?id=ed1957ad66206400aa38e5738a92e74edc45daa437de09bdc89fa2634ed6800e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1839564383/image_1839564383.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Dogs of the Dow look overvalued, with no must-buy dividend signals.",
                "category": "company",
                "datetime": 1788422137,
                "headline": "Dogs Of The Dow: No Buys And Few Worth Watching"
              },
              {
                "id": 141396877,
                "url": "https://finnhub.io/api/news?id=c79fadb8c7424c24b8db9fce5e390a61f7312a0a55cc2ab006bd9eb2cb5a23c4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2286477227/image_2286477227.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.",
                "category": "company",
                "datetime": 1788417365,
                "headline": "Moderna: Massive Asymmetry About What The mRNA Is!"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379441,
                "url": "https://finnhub.io/api/news?id=62e773579e3a62df81afcdad4037a0fd886c9dbd055e0ac4c015a53682f0fe97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.",
                "category": "company",
                "datetime": 1788369887,
                "headline": "Beyond The Cloud Giants: What Could Power NVIDIA Stock From Here?"
              },
              {
                "id": 141379514,
                "url": "https://finnhub.io/api/news?id=be26bbec50ca5a5b43eebb50858927fd3ecc60fec2a00862e209b8f346cbf49c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.",
                "category": "company",
                "datetime": 1788361800,
                "headline": "AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks"
              },
              {
                "id": 141379511,
                "url": "https://finnhub.io/api/news?id=8780cdd6f1f1fad15e05dfd24f46c854de4ccc02b6ab97af39ced883123d9239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.",
                "category": "company",
                "datetime": 1788361620,
                "headline": "Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?"
              },
              {
                "id": 141376479,
                "url": "https://finnhub.io/api/news?id=2d029860b216fddfbff397866faf68627b7d0e5e085bc67947d73b47a2b94314",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "FINN Partners, one of the world's largest independent communication, public affairs and marketing firms, today announced that Jeffrey L. Sturchio, PhD, is joining as a senior adviser. He will be part of FINN's Global Health Practice and work with the Health Policy and Impact Group. Dr. Sturchio's appointment strengthens a multinational team whose expertise spans health policy, stakeholder engagement, communications and purpose, adding one of global health's most respected advisors to its ranks.",
                "category": "company",
                "datetime": 1788357600,
                "headline": "Global Health Leader Jeffrey L. Sturchio, PhD, Joins FINN Partners' Health Policy and Impact Group as Senior Advisor"
              },
              {
                "id": 141376478,
                "url": "https://finnhub.io/api/news?id=70f5ee04c17fec2fc81eed793a9d35075ea371422f06bbe803a55e67af6db3aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 02, 2026--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference",
                "category": "company",
                "datetime": 1788349500,
                "headline": "Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference"
              },
              {
                "id": 141373098,
                "url": "https://finnhub.io/api/news?id=3b8ae9abd0431d10053f8279b998a980036723c7d887184dd5f43c60a6006a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...",
                "category": "company",
                "datetime": 1788311942,
                "headline": "Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?"
              },
              {
                "id": 141369874,
                "url": "https://finnhub.io/api/news?id=d712d75c450835888382f0049c3dfaaa54fd8760a7b25a62dc9c11038231ace7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.",
                "category": "company",
                "datetime": 1788291120,
                "headline": "Can Bixlenvo Unlock New Growth for Gilead's HIV Business?"
              },
              {
                "id": 141370623,
                "url": "https://finnhub.io/api/news?id=2811d09bc453d60ad535201a16e94c17326b4e0711eab591a46c0c53c4effcac",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Tuesday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1788289805,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 141369875,
                "url": "https://finnhub.io/api/news?id=25713ea44798b5c5338ef99e3f48cdcdce18c543fa8e5a8f3d3b44d5e44b9a8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.",
                "category": "company",
                "datetime": 1788289217,
                "headline": "Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III"
              },
              {
                "id": 141369876,
                "url": "https://finnhub.io/api/news?id=b4b729cd08099e1154aab3a209d040b8a59a911ae8a6cb3d1379f2bf2e6d31aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.",
                "category": "company",
                "datetime": 1788288240,
                "headline": "Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023."
              },
              {
                "id": 141378635,
                "url": "https://finnhub.io/api/news?id=e4e18d878304530ff690fd40e3e9194a40a530d4efe228b4c517b51541d5d5b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108353953-1787671978491-Traders-20260825-AS-PRESS-7.jpg?v=1787672206&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Stocks rose on Wednesday as U.S. Treasury yields took a breather from the recent run-up that sent them to multiyear highs.",
                "category": "company",
                "datetime": 1788285670,
                "headline": "Stocks rise for first time in four sessions as Treasury yields take breather: Live updates"
              },
              {
                "id": 141369872,
                "url": "https://finnhub.io/api/news?id=22f605547bfacbaac2c154f62577d8e98379a41e3d1a13b76ad364bcf8dcf597",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "DelveInsight's PCSK9 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Dyslipidemia, Hypercholesterolemia (Familial + Non-Familial), ASCVD, Coronary Revascularization (CABG and PCI), ACS (Acute Myocardial Infarction & Unstable Angina), and others. The selected indications are based on approved therapies and o",
                "category": "company",
                "datetime": 1788276660,
                "headline": "The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight"
              },
              {
                "id": 141369873,
                "url": "https://finnhub.io/api/news?id=1bce6207890c6536b7e9eb485b632e6b759d6d03e2e31443e056c8d59c8c4270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.",
                "category": "company",
                "datetime": 1788276420,
                "headline": "Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough"
              },
              {
                "id": 141361001,
                "url": "https://finnhub.io/api/news?id=9315fd4dd75780eaab7805f262d6a791796b33062bb781fa99191d618e904bc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock led the index after melanoma vaccine data, while a hedge fund's forced unwind turbocharged a rebound in enterprise software",
                "category": "company",
                "datetime": 1788269873,
                "headline": "S&P 500 biggest August 2026 winners: Moderna, software stocks"
              },
              {
                "id": 141369345,
                "url": "https://finnhub.io/api/news?id=3e8db54c0b5ab5e1fcd7fd29a36003db9ca2ac1882435469d32ca71af62e3594",
                "image": "https://image.cnbcfm.com/api/v1/image/108219605-1761852273367-gettyimages-2243467825-APPLE_EARNS.jpeg?v=1788283461&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1788269185,
                "headline": "Stocks making the biggest moves midday: Palo Alto Networks, Fervo Energy, Chevron, Apple & more"
              },
              {
                "id": 141361115,
                "url": "https://finnhub.io/api/news?id=5106c7ff5b070fe0c7b6a173a3f38e02b4b2fe6602ed7eebd44bf5318c8e2fe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.",
                "category": "company",
                "datetime": 1788266040,
                "headline": "Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths"
              },
              {
                "id": 141369496,
                "url": "https://finnhub.io/api/news?id=4f91f46ba2696ef86a00fd668abea30ee391a07d5822b5a8219287f5f296dad8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/01/Skin-Cancer-Risk-Remains-High.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.",
                "category": "company",
                "datetime": 1788265512,
                "headline": "Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs"
              },
              {
                "id": 141361110,
                "url": "https://finnhub.io/api/news?id=d5ff30661b36ade78c981291fb8200bfdc2b3593b5b7a0f879ffc1bdf536d503",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.",
                "category": "company",
                "datetime": 1788263097,
                "headline": "Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy"
              },
              {
                "id": 141360400,
                "url": "https://finnhub.io/api/news?id=aa7198b5978cf502913b0190ebe77a269e3448592ea208728fb14c7eaf1f8928",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788255000,
                "headline": "4 Reasons Why SCHD May Be In A Trouble (Rating Downgrade)"
              },
              {
                "id": 141360369,
                "url": "https://finnhub.io/api/news?id=c1f6f6beede1420f94c162a824c404f259652bdfbddaae165962835edda18e54",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788254200,
                "headline": "Exelixis: \"Hold\" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data"
              },
              {
                "id": 141361116,
                "url": "https://finnhub.io/api/news?id=00d5e7c3f39d64edeb80638ea6187af7e328a3c5e29fd488b3fc67e6c2ccf850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company may be on track to its next product.",
                "category": "company",
                "datetime": 1788253801,
                "headline": "Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?"
              },
              {
                "id": 141361111,
                "url": "https://finnhub.io/api/news?id=84a3369fca40d74a20da124b5e8d22c4b306dc479750442df4f31fc296463d5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]",
                "category": "company",
                "datetime": 1788245094,
                "headline": "Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally"
              },
              {
                "id": 141361117,
                "url": "https://finnhub.io/api/news?id=6593cd0517ad32cbdb541210175453331bb3059dc150c87637f7d4fc6e86bbc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.",
                "category": "company",
                "datetime": 1788213900,
                "headline": "There Was No Beating Moderna in August. These Are the Best and Worst S&P 500 Stocks for the Month."
              },
              {
                "id": 141356417,
                "url": "https://finnhub.io/api/news?id=70b9550024f8c5d254fc55828103b4b095d43a0883efa08bacf46c4e37fc2a76",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Monday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1788203418,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 141369119,
                "url": "https://finnhub.io/api/news?id=a0c7014a0e603d59693dc159665135a67a694ca0ea0155eeaf780b43cad0d380",
                "image": "https://image.cnbcfm.com/api/v1/image/108356724-17882112331788211231-48101579622-1080pnbcnews.jpg?v=1788211232&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Michael Yee, UBS, joins 'Closing Bell Overtime' to talk the state of the biotech and pharmaceutical sectors.",
                "category": "company",
                "datetime": 1788197636,
                "headline": "UBS Michael Yee: We've been quite bullish on the pharma sector"
              },
              {
                "id": 141360884,
                "url": "https://finnhub.io/api/news?id=352ccb9dbc196e7fd72c636ec84aecaf01f3e6b3516908358b7cc115d9b040a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.",
                "category": "company",
                "datetime": 1788194220,
                "headline": "From Padcev to PF-08634404: Pfizer's Oncology Growth Push"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141356002,
                "url": "https://finnhub.io/api/news?id=e31bb94ba8ba5bf570eec0910d8d4a76f8de5cb1337c82447b88712cea7dea53",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266615986/image_2266615986.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "After outperforming its benchmark in 1Q2026, the Nomura Value Fund Institutional Class shares lost considerable ground to the Russell 1000® Value Index in 2Q2026. Read more here.",
                "category": "company",
                "datetime": 1788185460,
                "headline": "Nomura Value Fund Q2 2026 Portfolio Activity"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141361112,
                "url": "https://finnhub.io/api/news?id=d8d9f29d23f8ccc5a8039fb4f8d576454a33559eca689894c965058ad1ebf9a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least. The former’s stock closed 12.6% higher and the latter’s stock closed 176% higher on August 19th. The stocks surged after a major announcement from Moderna Inc. (NASDAQ:MRNA) shared the results from its […]",
                "category": "company",
                "datetime": 1788158154,
                "headline": "Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging"
              },
              {
                "id": 141361119,
                "url": "https://finnhub.io/api/news?id=5567db3cbce531d3c4fd84a637eb2aacb230997017083d16e7448c6d05940a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "SCHD just delivered a return most dividend investors spend a decade waiting for, and that success created a problem nobody predicted. Whether fresh money belongs in the fund right now depends on a tradeoff that long-term holders never had to face.",
                "category": "company",
                "datetime": 1788132325,
                "headline": "SCHD Is Up Nearly 30% and Its Yield Is Back Near 3% | Did Dividend Investors Miss the Easy Money?"
              },
              {
                "id": 141361106,
                "url": "https://finnhub.io/api/news?id=330a0319a7e0635308b52b8c3af730970549573bdd7e850be38befb61f99a2d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck has surged past the broader Nasdaq Composite over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.",
                "category": "company",
                "datetime": 1788120934,
                "headline": "Is Merck Stock Outperforming the Nasdaq?"
              },
              {
                "id": 141361107,
                "url": "https://finnhub.io/api/news?id=604a74c67cc76ee833e91a11b652ccba9c35816d3796c281b4852b3f31915326",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) and Moderna report the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The therapy was tested in combination with Merck's immunotherapy KEYTRUDA in a Phase 3 trial setting. This marks the first time an mRNA-based individualized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer. The result signals a potential new path for personalized cancer vaccines with...",
                "category": "company",
                "datetime": 1788095722,
                "headline": "Merck (MRK) Posts First Positive Phase 3 Result For Personalized mRNA Melanoma Therapy"
              },
              {
                "id": 141361108,
                "url": "https://finnhub.io/api/news?id=4283f23d94cd6939bf9492a401776c8818a3837d266c5cd9700d5961e27b7c07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna Inc. (NASDAQ:MRNA) and Merck […]",
                "category": "company",
                "datetime": 1788087780,
                "headline": "Healthcare’s Best Week Since June Traces Back to a Single Moderna and Merck Cancer Trial"
              },
              {
                "id": 141361113,
                "url": "https://finnhub.io/api/news?id=66fec465e4c89bac40a78eb914eb8ac5d4d59922ab72ad142eae213f419a9b70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replied: Here’s what I would do: I think that you have to […]",
                "category": "company",
                "datetime": 1787952295,
                "headline": "Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial"
              },
              {
                "id": 141348569,
                "url": "https://finnhub.io/api/news?id=5caec48fa8c298b9b7ae22abf3e8a0748a26e4cee3ef928bc307c833666febd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The signs were not in the headline growth rate but in which two products were trading places.",
                "category": "company",
                "datetime": 1787947785,
                "headline": "Did A Product Swap Fuel JNJ Stock’s 54% Surge?"
              },
              {
                "id": 141361121,
                "url": "https://finnhub.io/api/news?id=768a75ca19c35df540bbddc98ae5977f685be591565b6a60990acc1b1816a6b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.",
                "category": "company",
                "datetime": 1787946240,
                "headline": "BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win"
              },
              {
                "id": 141348570,
                "url": "https://finnhub.io/api/news?id=4f0e161ba9b9cba902841c73156b0682cae4aa772893993f336979cf573e608d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.",
                "category": "company",
                "datetime": 1787945738,
                "headline": "Can Merck Stock Outrun Its Pipeline?"
              },
              {
                "id": 141339387,
                "url": "https://finnhub.io/api/news?id=5b27de5152d79b81f60ff69ee0c2f519f474646bac52a822fe2fd7513d0b0db2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Friday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1787944206,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 141361124,
                "url": "https://finnhub.io/api/news?id=f706f1ea4a86a23d6768be3b0540c0f35678d639d8b0ceb699785025db0631a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical",
                "category": "company",
                "datetime": 1787942820,
                "headline": "BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall"
              },
              {
                "id": 141361123,
                "url": "https://finnhub.io/api/news?id=a229776adfbd2f478759fe9524731e4ae216e3235018194f23142aea4be40078",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients.",
                "category": "company",
                "datetime": 1787941321,
                "headline": "BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’"
              },
              {
                "id": 141338491,
                "url": "https://finnhub.io/api/news?id=55cae651cbeff84fbf63cc5a69133b5bb10f6b6420ada6c314a3e1af3a9e0019",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787935206,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 141338793,
                "url": "https://finnhub.io/api/news?id=bd81a66323ddaec8a6c063ad55e9bab105eb706d36589a0de58b89f58003aded",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report",
                "category": "company",
                "datetime": 1787921002,
                "headline": "World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency"
              },
              {
                "id": 141332704,
                "url": "https://finnhub.io/api/news?id=5433b90d434ccadf5fa25840410d7ff01912ef51cbc03381fbdc7a0328c91add",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.",
                "category": "company",
                "datetime": 1787864703,
                "headline": "What's going on in today's after hours session: S&P500 movers"
              },
              {
                "id": 141332703,
                "url": "https://finnhub.io/api/news?id=d854a50559f4c80953210ae0c5c722cc139602482c61ff4b2f8fc1ded4d1a701",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.",
                "category": "company",
                "datetime": 1787864400,
                "headline": "Stay updated with the stocks that are on the move in today's after-hours session."
              },
              {
                "id": 141332096,
                "url": "https://finnhub.io/api/news?id=f91bace257ba0af744e76346de1ee986e0b1ace6e3fd1e564f4da44e81506cdf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1787857806,
                "headline": "Thursday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141331062,
                "url": "https://finnhub.io/api/news?id=5c23c716656d25f98d61da7895898b299ef98b2bd2a7cea04355a7c099030532",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1787848807,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 141331717,
                "url": "https://finnhub.io/api/news?id=b76b2b2c443ab9cdc5e0d7b1f80faa2c059934c65cbfad7ab85c3c4e47c4c2d8",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787837726,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 141331719,
                "url": "https://finnhub.io/api/news?id=997531e2ee255677892a76e5ee557d2bbc12a11a127519612b721cb6ab5be5c9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.",
                "category": "company",
                "datetime": 1787823061,
                "headline": "Moderna Borrows $2 Billion To Expand Oncology Business"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 241,
            "discarded_article_count": 221
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.4,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(18.9%→7.6%)；跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 11052718.466666667,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 10901485.4,
              "avg_vol_20": 10013867.7,
              "avg_vol_30": 11052718.466666667,
              "range_pct_10": 0.07597244629966982,
              "range_pct_20": 0.09859528500006362,
              "range_pct_30": 0.18915450852033341,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.986317115818813,
              "dist_to_20d_high": 0.05633442518480742,
              "down_shrink_days": 3,
              "breakout_level_20d": 156.92,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4016422706176367
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.1995542652680404,
              "turnoverUsdM": 1426.1195542214741,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRK",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 141.5658,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.4,
            "take_profit_price": 155.484,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.399108530536081,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 3.2571,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.2
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 19.24
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0117
    },
    "kdj": {
      "d": 50.64,
      "j": 75.47,
      "k": 58.92,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 53.95
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 21709717,
      "recentSlope": -1296288.3,
      "previousSlope": -3405160
    },
    "rsi": 41.76,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 142.545,
      "position": "SAR喺價下",
      "distancePct": 3.74,
      "previousTrend": "上升"
    },
    "ma50": 139.473,
    "macd": {
      "macd": 1.9884745705235503,
      "trend": "中性偏多",
      "signal": 2.4408721478977764,
      "histogram": -0.45239757737422615
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 148.0353,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 3
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.98,
      "score": 4,
      "avgVolume": 9795150,
      "currentVolume": 9630737
    },
    "derived": {
      "ma20": 148.1805,
      "ma50": 139.473,
      "prevClose": 150.91,
      "avgVolume10": 11009959,
      "avgVolume20": 9795150,
      "changePercent": -1.88,
      "avgVolumeForScore": 9795150
    },
    "ma_cross": {
      "ma20": 148.1805,
      "ma50": 139.473,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 148.599,
      "prevMa50": 138.927,
      "spreadPct": 6.24,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 142.7653,
      "upper": 153.5957,
      "position": "中間"
    },
    "rsi_short": 70.41,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.98
    }
  }
}

{
  "close": 148.08,
  "volume": 9630737,
  "changePercent": -1.88
}